Investigating documented reasons for withdrawal from clinical trials for patients with advanced prostate cancer (PCa) von Lloyd, Jennifer, Nordblad, Blake, Sahu, Kamal Kant Kant, Swami, Umang, Phunrab, Tenzin Kunsang, Batten, Julia Anne, Maxwell, Lindsay, Kohli, Manish, Gupta, Sumati, Maughan, Benjamin L., Agarwal, Neeraj

Volltext

Randomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) versus EZ alone in metastatic castration-refractory prostate cancer (mCRPC): Long-term follow up of secondary en... von Maughan, Benjamin Louis, Hahn, Andrew W, Nussenzveig, Roberto, Hoffman, John, Morton, Kathryn, Gupta, Sumati, Batten, Julia Anne, Thorley, Jared, Hawks, Josiah, Santos, Victor Sacristan, Nachaegari, Gayatri, Wang, Xuechen, Boucher, Kenneth M., Haaland, Benjamin, Agarwal, Neeraj

Volltext

Safety data from a phase II randomized trial of radium-223 dichloride (Ra-223) plus enzalutamide (Enza) vs. Enza alone in men with metastatic castration refractory prostate cancer... von Maughan, Benjamin Louis, Hoffman, John M., Morton, Kathryn, Koppula, Bhasker, Batten, Julia Anne, Thorley, Jared, Hawks, Josiah, Boucher, Kenneth, Agarwal, Neeraj

Volltext

Evolution of the genomic landscape of circulating tumor DNA (ctDNA) in advanced prostate cancer (aPC) over treatment and time von Stenehjem, David D., Hahn, Andrew W, Nussenzveig, Roberto, Carroll, Emma, Gill, David Michael, Bailey, Erin B., Batten, Julia Anne, Maughan, Benjamin Louis, Agarwal, Neeraj

Volltext

Clinical outcomes and survival of patients (pts) with sarcomatoid metastatic renal cell carcinoma (smRCC) von Tantravahi, Srinivas Kiran, Stenehjem, David D., Agarwal, Archana, Kollepara, Sri Lakshmi S., Batten, Julia Anne, Ward, Michael, Albertson, Dan, Wang, Junfeng, Liu, Ting, Agarwal, Neeraj

Volltext

Clinical benefit (CB) of high-dose interleukin-2 (HD IL-2) in clear cell (cc) metastatic renal cell carcinoma (mRCC) von Agarwal, Neeraj, Parikh, Kinjal, Tantravahi, Srinivas Kiran, Crispin, Hilda, Van Atta, Joan, Batten, Julia Anne, Sageser, Daniel, Samlowski, Wolfram E., Grossmann, Kenneth F., Wang, Junfeng, Stenehjem, David D.

Volltext

Conditional survival (CS) of metastatic renal cell carcinoma (mRCC) patients treated with high dose interleukin-2 (HD IL-2) von Parikh, Kinjal, Stenehjem, David D., Sendilnathan, Arun, Crispin, Hilda, Van Atta, Joan, Batten, Julia Anne, Sageser, Daniel, Grossmann, Kenneth F., Wang, Junfeng, Samlowski, Wolfram E., Tantravahi, Srinivas Kiran, Agarwal, Neeraj

Volltext

Association between rigors and overall survival (OS) in metastatic renal cell carcinoma (mRCC) patients treated with high-dose interleukin-2 (HD IL-2) von Batten, Julia Anne, Samlowski, Wolfram E., Parikh, Kinjal, Sendilnathan, Arun, Crispin, Hilda, Van Atta, Joan, Sageser, Daniel, Grossmann, Kenneth F., Wang, Junfeng, Tantravahi, Srinivas Kiran, Stenehjem, David D., Agarwal, Neeraj

Volltext

Association of clinical parameters and overall survival (OS) in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with high-dose interleukin-2 (HD IL-2) von Stenehjem, David D., Parikh, Kinjal, Batten, Julia Anne, Van Atta, Joan, Crispin, Hilda, Sageser, Daniel S., Grossmann, Kenneth F., Wang, Junfeng, Tantravahi, Srinivas Kiran, Samlowski, Wolfram E., Agarwal, Neeraj

Volltext

The effect of prior abiraterone (Abi) use on the activity of enzalutamide (Enza) in men with mCRPC von Cheng, Heather H., Nadal, Rosa, Gulati, Roman, Azad, Arun, Twardowski, Przemyslaw, Vaishampayan, Ulka N., Agarwal, Neeraj, Heath, Elisabeth I., Pal, Sumanta Kumar, Rehman, Hibba-tul, Leiter, Amanda, Batten, Julia Anne, Montgomery, Robert B., Galsky, Matt D., Chi, Kim N., Antonarakis, Emmanuel S., Yu, Evan Y.

Volltext